European Radiology:深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值

2021-12-28 shaosai MedSci原创

肝细胞肝癌(HCC)的根治性切除术是早期HCC患者的第一选择。然而,术后2年的复发率很高,达到50%。

肝细胞癌(HCC)的根治性切除是早期HCC患者的第一选择。然而,术后2年的复发率很高,达到50%。微血管侵犯(MVI)是肿瘤侵袭性、切除后肿瘤复发和生存率低的一个重要指标。

影像学有助于预测HCC的MVI。深度学习是人工智能(AI)的一个子集,可以自动学习样本图像中的特征表示,应用于医学的图像识别和判析其中高性能深度卷积神经网络(DCNN)是新兴的技术之一然而据我们所知基于DCNN的MVI的诊断和预后方面的文献有限,需要进一步的研究进行评估

近日,发表在European Radiology杂志的一项研究探讨了DCNN在大量HCC手术候选人中使用对比增强CT扫描(CECT)识别MVI以及预测临床预后的性能为临床术前的准确评估及质量方案的制定提供了影像学参考依据

本项回顾性研究包括1116名接受术前CECT和根治性肝切除术的HCC患者。根据临床放射学因素、DCNN概率和所有因素,分别在训练队列(n = 892)中构建了放射学(R)、DCNN和组合列线图;每个模型的性能在验证队列(n = 244)中得到确认。计算了预测MVI的准确率和AUC记录了手术后的无病生存(DFS)和总生存(OS)。 

在训练和验证队列中,MVI阳性患者的比例分别为38.8%(346/892)和35.7%(87/244)。在训练队列中,R、DCNN和组合列线图的AUCs分别为0.809、0.929和0.940,在验证队列中为0.837、0.865和0.897。在训练组(p < 0.001)和验证组(p = 0.009),组合列线图的表现优于R列线图。在R、DCNN和组合列线图预测的有MVI和无MVI的组别中,DFS和OS有显著差异(p < 0.001)。 

 a 使用三期相DCNN概率构建的DCNN列线图。 b DCNN列线图在训练和验证队列中预测MVI的ROC分析曲线。DCNN,深度卷积神经网络;MVI,微血管侵袭

本研究通过结合临床因素和基于术前CECT的放射学特征建立了一个联合列线图,可用于术前预测MVI。同时该组合列线图还可以预测DFS和OS为临床个性化治疗方案的制定提供了无创影像学参考依据

原文出处

Xinming Li,Zhendong Qi,Haiyan Du,et al.Deep convolutional neural network for preoperative prediction of microvascular invasion and clinical outcomes in patients with HCCs.DOI:10.1007/s00330-021-08198-w

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1729256, encodeId=43151e29256a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 18 16:23:29 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259557, encodeId=0c56125955ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365429, encodeId=895a136542925, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534779, encodeId=37f71534e7983, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630371, encodeId=a9d916303e1fd, content=<a href='/topic/show?id=44e0e449217' target=_blank style='color:#2F92EE;'>#神经网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74492, encryptionId=44e0e449217, topicName=神经网络)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ff21497204, createdName=by2016, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=)]
    2022-06-18 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1729256, encodeId=43151e29256a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 18 16:23:29 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259557, encodeId=0c56125955ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365429, encodeId=895a136542925, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534779, encodeId=37f71534e7983, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630371, encodeId=a9d916303e1fd, content=<a href='/topic/show?id=44e0e449217' target=_blank style='color:#2F92EE;'>#神经网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74492, encryptionId=44e0e449217, topicName=神经网络)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ff21497204, createdName=by2016, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=)]
    2021-12-30 jiyangfei
  3. [GetPortalCommentsPageByObjectIdResponse(id=1729256, encodeId=43151e29256a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 18 16:23:29 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259557, encodeId=0c56125955ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365429, encodeId=895a136542925, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534779, encodeId=37f71534e7983, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630371, encodeId=a9d916303e1fd, content=<a href='/topic/show?id=44e0e449217' target=_blank style='color:#2F92EE;'>#神经网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74492, encryptionId=44e0e449217, topicName=神经网络)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ff21497204, createdName=by2016, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=)]
    2021-12-30 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1729256, encodeId=43151e29256a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 18 16:23:29 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259557, encodeId=0c56125955ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365429, encodeId=895a136542925, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534779, encodeId=37f71534e7983, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630371, encodeId=a9d916303e1fd, content=<a href='/topic/show?id=44e0e449217' target=_blank style='color:#2F92EE;'>#神经网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74492, encryptionId=44e0e449217, topicName=神经网络)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ff21497204, createdName=by2016, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1729256, encodeId=43151e29256a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 18 16:23:29 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259557, encodeId=0c56125955ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365429, encodeId=895a136542925, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534779, encodeId=37f71534e7983, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630371, encodeId=a9d916303e1fd, content=<a href='/topic/show?id=44e0e449217' target=_blank style='color:#2F92EE;'>#神经网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74492, encryptionId=44e0e449217, topicName=神经网络)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ff21497204, createdName=by2016, createdTime=Thu Dec 30 07:23:29 CST 2021, time=2021-12-30, status=1, ipAttribution=)]

相关资讯

Radiology:在预测慢性乙型肝炎HCC的进展中,你知道这一评分系统吗?

乙型肝炎病毒(HBV)感染是导致肝硬化、肝衰竭和肝细胞癌(HCC)等终末期肝病的最常见原因之一。

AJG:酒精性肝硬化患者戒酒对肝细胞癌风险的影响

酒精性脂肪肝是由于长期大量饮酒导致的肝脏疾病,是酒精性肝病中的一个分型。

European Radiology:Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测

肝细胞肝癌(HCC)是最常见的肝脏恶性肿瘤之一,是全球癌症相关死亡的第三大原因。目前,手术切除和肝移植是HCC患者的有效治疗方式,但术后复发和转移十分常见。

AP&T: 慢性病毒性肝炎并发脂肪肝的肝细胞癌风险和死亡率会明显增加

肝细胞癌(HCC)是肝癌的主要组织学亚型,占原发性肝癌的90%,是全世界癌症相关死亡率的第三大常见原因。

Radiology:MRI,让增殖型HCC“一眼到底”!

众所周知,肝细胞肝癌(HCC)在基因组、分子和组织学层面的异质性较强。越来越多的证据表明,分子和组织形态学特征之间的相关性,导致了HCC的几种组织学变体的提出。

Br J Cancer:晚期肝细胞癌患者诊断性活检的可行性分析

早在2001年欧洲肝脏研究协会(EASL)首次定义了用于诊断肝细胞癌(HCC)的无创放射学标准(NIRC),并随着时间的推移不断的完善该标准。